来自官方财务报表的收入、利润与现金流历史。
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $1.5B | $1.4B | $1.2B | $1.1B | $847M | $748M | $560M | $547M | $445M | $334M | $263M | $186M | $126M | $89M | $73M |
| 毛利 | $1.0B | $942M | $755M | $683M | $535M | $475M | $338M | $372M | $293M | $217M | $171M | $124M | $83M | $58M | $49M |
| 毛利率% | 67.8% | 67.1% | 63.2% | 64.5% | 63.2% | 63.6% | 60.3% | 68.0% | 65.8% | 65.1% | 64.9% | 66.7% | 66.0% | 65.1% | 66.9% |
| 营业利润（EBIT） | $187M | $189M | $9M | $74M | $6M | ($8M) | ($39M) | $48M | ($1M) | $1M | ($1M) | $4M | $3M | ($1M) | $3M |
| 营业利润率% | 12.4% | 13.5% | 0.8% | 7.0% | 0.7% | -1.0% | -7.0% | 8.7% | -0.2% | 0.4% | -0.5% | 2.2% | 2.4% | -1.3% | 4.7% |
| 净利 | $161M | $178M | $14M | $91M | ($2M) | $3M | ($19M) | $48M | $7M | $5M | $15M | $2M | $2M | $4M | $2M |
| 净利润率 % | 10.7% | 12.7% | 1.2% | 8.6% | -0.2% | 0.4% | -3.4% | 8.8% | 1.5% | 1.4% | 5.6% | 1.3% | 1.8% | 4.6% | 2.7% |
| EBITDA | — | $223M | $46M | $109M | $30M | $9M | ($26M) | $56M | $36M | $5M | $1M | $6M | $4M | $0M | $3M |
| 每股收益（EPS） | $4.07 | $4.52 | $0.36 | $2.32 | $-0.05 | $0.07 | $-0.54 | $1.34 | $0.18 | $0.13 | $0.44 | $0.17 | $0.09 | $0.17 | $0.08 |
| 已发行股数 (M) | — | 39M | 39M | 39M | 38M | 38M | 36M | 36M | 36M | 35M | 33M | 14M | 25M | 25M | 25M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 PEN 交互式查看器。 /companies/us/PEN
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms